Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kaivalya Deshpande"'
Autor:
Shravanthi Chidambaram, Fernando J. Velloso, Deborah E. Rothbard, Kaivalya Deshpande, Yvelande Cajuste, Kristin M. Snyder, Eduardo Fajardo, Andras Fiser, Nikos Tapinos, Steven W. Levison, Teresa L. Wood
Publikováno v:
Stem Cell Reports. 17:1411-1427
The insulin receptor (INSR) is an evolutionarily conserved signaling protein that regulates development and cellular metabolism. INSR signaling promotes neurogenesis in Drosophila; however, a specific role for the INSR in maintaining adult neural ste
Publikováno v:
World Journal of Surgical Procedures. 8:1-5
Autor:
Eduardo Fajardo, Nikos Tapinos, Andras Fiser, Teresa L. Wood, Shravanthi Chidambaram, Kaivalya Deshpande, Deborah E. Rothbard, Yvelanda Cajuste, Kristin M. Snyder, Steven W. Levison
SummaryThe insulin receptor (IR) is an evolutionarily conserved signaling protein that regulates development and cellular metabolism. IR signaling regulates neurogenesis in Drosophila; however, a specific role for the IR in maintaining adult neural s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb394be1be89800b528bf029f7caaa8e
Publikováno v:
World Journal of Clinical Cases
Biosimilars are a growing drug class designed to be used interchangeably with biologics. Biologics are created in living cells and are typically large, complex proteins that may have a variety of uses. Within the field of gastroenterology alone, biol
Publikováno v:
World Journal of Gastroenterology
The field of medical and surgical weight loss is undergoing an explosion of new techniques and devices. A lot of these are geared towards endoscopic approaches rather than the conventional and more invasive laparoscopic or open approach. One such rec
Autor:
Arpita Vyas, Nicolas Lopez-Hisijos, Lakshmi S. Chaturvedi, Kaivalya Deshpande, Marc D. Basson, Dinesh Vyas, Pranav Shah
Publikováno v:
Journal of Nanoscience and Nanotechnology. 17:175-185
Triple-Negative Breast Cancer (TNBC) has a poor prognosis due to lack of targeted therapy. Doxorubicin (DOX) has failed for multiple reasons, including development of multi-drug resistance, induction of inflammation (IL-6 secretion) and long-term tox
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 21
Approximately 15-20% of breast cancer cases are diagnosed as Triple Negative Breast Cancer (TNBC), where there is a lack of expression of the Estrogen Receptor (ER), Progesterone Receptor (PR), and epidermal growth factor receptor 2 (HER2)..
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 21
One of the significant driving factors behind global trauma morbidity and mortality is underdeveloped and underrepresented pre-hospital care services in areas of need.
Publikováno v:
JAMA internal medicine. 179(4)
This study assesses whether American Thoracic Society clinical practice guidelines are substantiated by high-quality evidence and can be used to promote evidence-based medicine.
Publikováno v:
Journal of Clinical Medicine Research
Triple negative breast cancer (TNBC) comprises 17-20% of all breast cancers and is one of the most common breast cancers. The lack of therapy and failure of existing therapy has been a challenge for clinicians. Doxorubicin (DOX) is the first-line the